ImmuPharma plc (AIM: IMM) has appointed Kymos Group as its bioanalytical contract research organisation partner for the development of Kapiglucagon, its proprietary glucagon prodrug for Type 1 diabetes applications.
ImmuPharma appoints Thermo Fisher for drug production
ImmuPharma (AIM: IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished drug form of Kapiglucagon, its experimental diabetes treatment.
ImmuPharma highlights brain cancer potential for P140
ImmuPharma (AIM: IMM) has highlighted new academic research suggesting its lead drug candidate, P140, may have potential as a treatment for glioblastoma, one of the most aggressive and difficult-to-treat forms
ImmuPharma advances P140 partnering strategy following £6.5m raise
ImmuPharma PLC (AIM: IMM) said it is actively progressing partnering discussions for its lead autoimmune platform, P140, which remains its primary strategic focus for 2026.
ImmuPharma PLC advances P140 talks as new data strengthens programme
ImmuPharma PLC is stepping up efforts to secure a licensing deal for its P140 autoimmune platform, with discussions underway with multiple potential partners under confidentiality agreements.
Solvonis Therapeutics plc (LON: SVNS) Logo SVN-015 accepted into US NIDA funded programme
Solvonis’ Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction
ImmuPharma PLC (LON: IMM) Launch of New Website & Corporate Update
www.immupharma.co.uk
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir
Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its
Transforming Biotech: Insights from Tim McCarthy, CEO of ImmuPharma
ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of biotechnology, companies often face unique challenges, particularly when it comes to navigating public markets and
Immupharma PLC (LON:IMM) proves unique Mechanism of Action-P140
ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology
Faron Pharmaceuticals Ltd (AIM:FARN) Results of Oversubscribed Placing
Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Bookbuild, announced on 5 February 2025, is now closed.
Immupharma PLC (LON:IMM) Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases.